BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

624 related articles for article (PubMed ID: 17598009)

  • 1. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
    Abou-Nassar K; Kovacs MJ; Kahn SR; Wells P; Doucette S; Ramsay T; Clement AM; Khurana R; Mackinnon K; Blostein M; Solymoss S; Kingdom J; Sermer M; Rey E; Rodger M;
    Thromb Haemost; 2007 Jul; 98(1):163-71. PubMed ID: 17598009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation.
    Schambeck CM; Eberl E; Geisen U; Grossmann R; Keller F
    Thromb Haemost; 2001 May; 85(5):782-6. PubMed ID: 11372668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation activation markers do not correlate with the clinical risk of thrombosis in pregnant women.
    Bombeli T; Raddatz-Mueller P; Fehr J
    Am J Obstet Gynecol; 2001 Feb; 184(3):382-9. PubMed ID: 11228491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss.
    Sarig G; Blumenfeld Z; Leiba R; Lanir N; Brenner B
    Thromb Haemost; 2005 Nov; 94(5):980-5. PubMed ID: 16363240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in plasma coagulation markers with prophylactic treatment of low molecular weight heparin after cesarean section.
    Hirota Y; Sakai M; Nakabayashi M
    Semin Thromb Hemost; 2005 Jun; 31(3):253-60. PubMed ID: 16052393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation.
    Weitz IC; Israel VK; Waisman JR; Presant CA; Rochanda L; Liebman HA
    Thromb Haemost; 2002 Aug; 88(2):213-20. PubMed ID: 12195692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thrombophilia, preeclampsia and other pregnancy complications].
    Vucić N; Frleta M; Petrović D; Ostojić V
    Acta Med Croatica; 2009 Oct; 63(4):297-305. PubMed ID: 20034330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Xa inhibition and coagulation activity--the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals.
    Oldgren J; Johnston N; Siegbahn A
    Am Heart J; 2008 Mar; 155(3):493.e1-8. PubMed ID: 18294482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
    Wolzt M; Weltermann A; Nieszpaur-Los M; Schneider B; Fassolt A; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1995 Mar; 73(3):439-43. PubMed ID: 7667826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial.
    Rodger MA; Hague WM; Kingdom J; Kahn SR; Karovitch A; Sermer M; Clement AM; Coat S; Chan WS; Said J; Rey E; Robinson S; Khurana R; Demers C; Kovacs MJ; Solymoss S; Hinshaw K; Dwyer J; Smith G; McDonald S; Newstead-Angel J; McLeod A; Khandelwal M; Silver RM; Le Gal G; Greer IA; Keely E; Rosene-Montella K; Walker M; Wells PS;
    Lancet; 2014 Nov; 384(9955):1673-83. PubMed ID: 25066248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood.
    Heilmann L; Rath W; Pollow K; Bick RL
    Clin Hemorheol Microcirc; 2007; 37(3):211-8. PubMed ID: 17726250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of an optimal dose of low-molecular-weight heparin for thromboprophylaxis in pregnant women at risk of thrombosis using coagulation activation markers.
    Bombeli T; Raddatz Mueller P; Fehr J
    Haemostasis; 2001; 31(2):90-8. PubMed ID: 11684864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
    Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
    Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism.
    Schutgens RE; Esseboom EU; Snijder RJ; Haas FJ; Verzijlbergen F; Nieuwenhuis HK; Lisman T; Biesma DH
    J Lab Clin Med; 2004 Aug; 144(2):100-7. PubMed ID: 15322504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of prophylactic heparin treatment on enhanced thrombin generation in pregnancy.
    Bremme K; Lind H; Blombäck M
    Obstet Gynecol; 1993 Jan; 81(1):78-83. PubMed ID: 8416465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
    Brenner B; Hoffman R; Blumenfeld Z; Weiner Z; Younis JS
    Thromb Haemost; 2000 May; 83(5):693-7. PubMed ID: 10823264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A risk score for the management of pregnant women with increased risk of venous thromboembolism: a multicentre prospective study.
    Dargaud Y; Rugeri L; Vergnes MC; Arnuti B; Miranda P; Negrier C; Bestion A; Desmurs-Clavel H; Ninet J; Gaucherand P; Rudigoz RC; Berland M; Champion F; Trzeciak MC
    Br J Haematol; 2009 Jun; 145(6):825-35. PubMed ID: 19388925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy.
    Jacobsen AF; Qvigstad E; Sandset PM
    BJOG; 2003 Feb; 110(2):139-44. PubMed ID: 12618157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.